Oncology Companion Diagnostics Market
- 2026 年市場規模
- USD 5.47 Bn
- 2033 年預估規模
- USD 11.02 Bn
- 年複合成長率 CAGR
- 10.6%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
完整報告名稱與涵蓋範圍
Oncology Companion Diagnostics Market, By Product and Service (Kits and Reagents, Instruments, Services), By Technology (Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH), Other Technologies), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others), By End User (Hospitals and Cancer Centers, Diagnostic Laboratories, Pharmaceutical and Biotechnology Companies, Research Institutes, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
報告摘要
The global oncology companion diagnostics market is estimated to be valued at USD 5.47 Bn in 2026 and is expected to reach USD 11.02 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 10.6% from 2026 to 2033. The global oncology companion diagnostics market is revolutionizing the precision oncology arena to choose the patients and decide the treatment on the basis of biomarkers. The applications of companion diagnostics for targeted treatments in common cancers like breast, lung, colorectal and prostate cancers is increasing due to developments in genomics, proteomics and molecular testing.
The co-development of diagnostics and targeted treatments is expanding the clinical use of companion diagnostics and delineating their role in personalized cancer care. These tests serve to better stratify patients, inform treatment selection, and optimize therapeutic outcomes in an increasing number of biomarker-driven oncology treatment pathways.
Market Dynamics
The global oncology companion diagnostics market is driven by the expanding acceptance of personalized and precision oncology and the rising dependence on biomarker-based treatment choices for various cancers such as breast, lung, colorectal, and others. Developments in Next Generation Sequencing (NGS) and multiplex testing have improved detection capabilities for multiple biomarkers and aided in making decisions for targeted therapy.
However, the growth of oncology companion diagnostics market is limited by factors such as high development and validation costs, complex regulatory pathways, and reimbursement uncertainties across regions. Nevertheless, significant opportunities exist in increasing investments in healthcare in emerging markets, rise in the pipeline of biomarker-driven therapies, and growing use of AI for diagnostic interpretation.
Key Features of the Study
• This report provides in-depth analysis of the global oncology companion diagnostics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global oncology companion diagnostics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd., Agilent Technologies, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Illumina, Inc., Abbott Laboratories, Foundation Medicine, Inc., Guardant Health, Inc., Myriad Genetics, Inc., and bioMérieux S.A.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global oncology companion diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oncology companion diagnostics market
Market Segmentation
• Product and Service Insights (Revenue, USD Bn, 2021 - 2033)
o Kits and Reagents
o Instruments
o Services
• Technology Insights (Revenue, USD Bn, 2021 - 2033)
o Immunohistochemistry (IHC)
o Next-Generation Sequencing (NGS)
o Polymerase Chain Reaction (PCR)
o In Situ Hybridization (ISH)
o Other Technologies
• Cancer Type Insights (Revenue, USD Bn, 2021 - 2033)
o Breast Cancer
o Lung Cancer
o Colorectal Cancer
o Prostate Cancer
o Others
• End User Insights (Revenue, USD Bn, 2021 - 2033)
o Hospitals and Cancer Centers
o Diagnostic Laboratories
o Pharmaceutical and Biotechnology Companies
o Research Institutes
o Others
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
o North America
U.S.
Canada
o Latin America
Brazil
Argentina
Mexico
Rest of Latin America
o Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC Countries
Israel
Rest of Middle East
o Africa
South Africa
North Africa
Central Africa
• Key Players Insights
o F. Hoffmann-La Roche Ltd.
o Agilent Technologies, Inc.
o Thermo Fisher Scientific Inc.
o QIAGEN N.V.
o Illumina, Inc.
o Abbott Laboratories
o Foundation Medicine, Inc.
o Guardant Health, Inc.
o Myriad Genetics, Inc.
o bioMerieux S.A.
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Global Oncology Companion Diagnostics Market, By Product and Service
Global Oncology Companion Diagnostics Market, By Technology
Global Oncology Companion Diagnostics Market, By Cancer Type
Global Oncology Companion Diagnostics Market, By End User
Global Oncology Companion Diagnostics Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Impact Analysis
o Key Highlights
o Regulatory Scenario
o Product Launches/Approvals
o PEST Analysis
o PORTER’s Analysis
o Market Opportunities
o Industry Trends
4. Global Oncology Companion Diagnostics Market, By Product and Service, 2021-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Kits and Reagents
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Instruments
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Services
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Oncology Companion Diagnostics Market, By Technology, 2021-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Immunohistochemistry (IHC)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Next-Generation Sequencing (NGS)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Polymerase Chain Reaction (PCR)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o In Situ Hybridization (ISH)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Other Technologies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Oncology Companion Diagnostics Market, By Cancer Type, 2021-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Breast Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Lung Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Colorectal Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Prostate Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Oncology Companion Diagnostics Market, By End User, 2021-2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Hospitals and Cancer Centers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Diagnostic Laboratories
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Pharmaceutical and Biotechnology Companies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Research Institutes
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
8. Global Oncology Companion Diagnostics Market, By Region, 2021 - 2033, Value (USD Bn)
o Introduction
Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
Regional Trends
o North America
Introduction
Market Size and Forecast, By Product and Service, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, By Product and Service, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
o Brazil
o Argentina
o Mexico
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, By Product and Service, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
o Germany
o U.K.
o Spain
o France
o Italy
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, By Product and Service, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By End User,2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, By Product and Service, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
o GCC Countries
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, By Product and Service, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
o South Africa
o North Africa
o Central Africa
9. Competitive Landscape
o F. Hoffmann-La Roche Ltd.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Agilent Technologies, Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Thermo Fisher Scientific Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o QIAGEN N.V.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Illumina, Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Abbott Laboratories
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Foundation Medicine, Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Guardant Health, Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o Myriad Genetics, Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
o bioMerieux S.A.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
10. Analyst Recommendations
o Wheel of Fortune
o Analyst View
o Coherent Opportunity Map
11. References and Research Methodology
o References
o Research Methodology
o About us
Browse 32 market data tables and 28 figures on ‘Oncology Companion Diagnostics Market' - Global forecast to 2033
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們